tiprankstipranks
Trending News
More News >
Standard BioTools (LAB)
NASDAQ:LAB

Standard BioTools (LAB) AI Stock Analysis

Compare
449 Followers

Top Page

LA

Standard BioTools

(NASDAQ:LAB)

Rating:49Neutral
Price Target:
$1.00
▲(1.01%Upside)
The company's overall stock score reflects significant financial challenges and weak technical indicators. Financial performance is the most influential factor, highlighting ongoing profitability issues and cash flow concerns. While strategic initiatives and partnerships offer potential, they have not yet mitigated current financial and operational challenges.
Positive Factors
Earnings
LAB reported 1Q revenue slightly better than consensus estimates, which is a good result in light of ongoing macro pressures and share weakness.
Operational Performance
Cost and operational initiatives continue to bear fruit with an adjusted operating loss improving by about 45% year over year despite a tough backdrop.
Product Development
There are signs of improvement on the horizon with positive customer trends, strengthening sales funnel, and momentum with SomaScan.
Negative Factors
Management Changes
The CFO departure (personal reasons) is a negative surprise though mgmt is steadfast key drivers (synergies, ILMN partnership) are unchanged.
Market Conditions
Consumables and services were both light due to US academic customer softness and declining field services revenue.
Revenue Guidance
LAB posted its preannounced 4Q24 with disappointing initial 2025 revenue guidance of $165M-$175M vs. consensus of $186.9M.

Standard BioTools (LAB) vs. SPDR S&P 500 ETF (SPY)

Standard BioTools Business Overview & Revenue Model

Company DescriptionStandard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
How the Company Makes MoneyStandard BioTools generates revenue primarily through the sale of its analytical instruments and consumables. The company offers a range of products that cater to different aspects of biological research, including genomics and proteomics. Revenue streams include direct sales to research institutions and laboratories, as well as partnerships and collaborations with pharmaceutical companies that utilize its technology for drug discovery and development. Additionally, the company may earn from service agreements, training, and customer support related to its products. Significant factors contributing to its earnings include the growing demand for advanced research tools in the life sciences sector and its ability to innovate and create technologies that address emerging research needs.

Standard BioTools Earnings Call Summary

Earnings Call Date:May 06, 2025
(Q1-2025)
|
% Change Since: -6.60%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook. While the company showed strong financial discipline and growth in instrument sales, it faced notable revenue declines and challenges in the Americas academic market. Strategic initiatives in proteomics and partnerships offer promising future prospects but are yet to significantly offset current revenue challenges.
Q1-2025 Updates
Positive Updates
Positive Financial Improvements
Non-GAAP operating expenses decreased by 22% year-over-year, operating loss improved by 45%, and adjusted EBITDA improved by 29%. Cash burn reduced by 33% compared to the previous year.
Strategic Foothold in Proteomics
The company announced new SomaScan offerings and partnerships, particularly with Illumina, expanding their reach in clinical research. New product launches and strategic initiatives are driving interest and growth.
Strong Instrument Revenue Growth
Instrument revenue increased by 24% year-over-year, driven by demand for Hyperion XTi spatial imaging systems.
Negative Updates
Revenue Decline
Overall revenue for Q1 2025 was $40.8 million, down 10% year-over-year, with consumables revenue down 16% and services revenue down 16%.
Challenges in Americas Academia
A mid-teens percentage decline in Americas academic revenue is expected, with significant impacts on consumables and service revenue due to funding uncertainties.
Tariff Impacts
New tariff measures have added complexity and potential cost impacts, with some products now subject to a 10% tariff.
Company Guidance
In the first quarter of 2025, Standard BioTools reported revenue of $40.8 million, a 10% decline year-over-year, but in line with expectations. Despite challenges, including a dynamic operating environment and pressures from tariffs and funding, the company maintained its full-year revenue guidance of $165 million to $175 million. The revenue mix comprised 35% consumables, 19% instruments, and 43% services, with instruments showing double-digit growth driven by demand for the Hyperion XTi spatial imaging systems. The company also reported a 22% year-over-year improvement in non-GAAP operating expenses, with adjusted EBITDA improving by 29%. With $261 million in cash and equivalents and no material debt, Standard BioTools remains focused on managing costs and driving operational efficiencies, with an eye on achieving adjusted EBITDA profitability by 2026.

Standard BioTools Financial Statement Overview

Summary
Standard BioTools faces significant financial challenges with consistent net losses and declining revenue. While balance sheet improvements exist, such as increased equity, the company's poor cash flow generation and persistent operating losses pose substantial risks to financial sustainability.
Income Statement
35
Negative
The company has experienced a decline in revenue over recent years, with Total Revenue decreasing from $138.1 million in 2020 to $106.3 million in 2023. Gross Profit Margin remains stable but negative Net Profit Margins indicate continuous losses. EBIT and EBITDA margins are negative, mirroring sustained operating losses. The revenue growth is negative, reflecting challenges in the company's ability to expand its market presence.
Balance Sheet
42
Neutral
The balance sheet shows a moderate level of stability with a strong equity base as Stockholders' Equity increased significantly by 2023. The Debt-to-Equity Ratio decreased, indicating lower financial leverage. The Equity Ratio has improved, suggesting a stronger asset base relative to equity. However, persistent losses impact overall financial health.
Cash Flow
30
Negative
The company's cash flow situation is concerning, with negative Free Cash Flow and Operating Cash Flow to Net Income ratios. Free Cash Flow has declined significantly, indicating poor cash generation capabilities. The Operating Cash Flow has been consistently negative, highlighting operational inefficiencies.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
174.43M106.34M97.95M130.58M138.14M
Gross Profit
84.26M50.45M37.05M69.37M83.33M
EBIT
-175.24M-76.60M-116.20M-67.46M-51.04M
EBITDA
-118.14M-54.46M-173.57M-43.77M-34.60M
Net Income Common Stockholders
-138.88M-74.66M-190.10M-59.24M-53.02M
Balance SheetCash, Cash Equivalents and Short-Term Investments
292.87M114.89M165.78M28.45M68.52M
Total Assets
612.34M323.07M390.31M275.21M324.76M
Total Debt
33.00M98.21M102.66M111.65M95.38M
Net Debt
-133.73M46.51M21.35M83.20M26.86M
Total Liabilities
140.62M159.87M471.78M180.62M185.71M
Stockholders Equity
471.72M163.20M-81.47M94.60M139.05M
Cash FlowFree Cash Flow
-151.81M-46.12M-93.19M-57.33M-28.13M
Operating Cash Flow
-143.45M-43.29M-89.37M-44.06M-15.42M
Investing Cash Flow
363.17M20.24M-88.13M-11.95M39.98M
Financing Cash Flow
-102.62M-6.81M230.76M15.96M20.86M

Standard BioTools Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.99
Price Trends
50DMA
1.11
Negative
100DMA
1.24
Negative
200DMA
1.57
Negative
Market Momentum
MACD
-0.02
Negative
RSI
43.45
Neutral
STOCH
70.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Negative. The current price of 0.99 is below the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.11, and below the 200-day MA of 1.57, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 43.45 is Neutral, neither overbought nor oversold. The STOCH value of 70.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LAB.

Standard BioTools Risk Analysis

Standard BioTools disclosed 53 risk factors in its most recent earnings report. Standard BioTools reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We may not realize all of the anticipated benefits of the Merger. Q4, 2024
2.
We have and will continue to incur direct and indirect costs as a result of the Merger and in connection with combining the businesses following the Merger. Q4, 2024
3.
Planned changes in the way that the FDA regulates tests performed by laboratories like ours will result in delay or additional expense in offering our tests and tests that we may develop in the future. Q4, 2024

Standard BioTools Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
$491.41M30.59-1.20%38.43%86.19%
59
Neutral
$648.14M-3.61%1.71%76.00%
57
Neutral
$454.87M-51.25%15.57%31.82%
54
Neutral
$5.28B3.29-45.38%2.80%16.77%-0.08%
OPOPK
52
Neutral
$1.09B-3.04%-13.79%82.82%
51
Neutral
$487.62M-13.84%12.15%61.33%
LALAB
49
Neutral
$410.21M-25.73%33.86%64.34%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
LAB
Standard BioTools
0.99
-1.33
-57.33%
MYGN
Myriad Genetics
4.92
-17.22
-77.78%
OPK
Opko Health
1.37
0.08
6.20%
FLGT
Fulgent Genetics
20.82
0.52
2.56%
PSNL
Personalis
5.06
3.71
274.81%
CSTL
Castle Biosciences
17.02
-6.13
-26.48%

Standard BioTools Corporate Events

Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Standard BioTools Q1 2025 Financial Results Overview
Neutral
May 6, 2025

Standard BioTools reported its financial results for the first quarter of 2025, showing a revenue of $40.8 million, a 10% decrease from the previous year. Despite the revenue decline, the company achieved a 45% reduction in operating loss and a 29% improvement in adjusted EBITDA, attributed to cost reductions and productivity gains. The company maintains a strong balance sheet with $261 million in cash and no material debt. The strategic focus on proteomics and the upcoming launch of a new NGS-based product are expected to drive future growth.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.